NASDAQ: ODTX
Odyssey Therapeutics, Inc.CIK 0001882782 · SIC 2836 · Biological Products
Small by assets
Assets $484M
as of Sep 6, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (MCFT 10-K) is open in full — no account needed.
8-K
Filed Sep 9, 2026
· Period ending Sep 8, 2026
Summary not yet generated.
10-Q
Filed Aug 6, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
Partner
Trade ODTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Aug 4, 2026
· Period ending Aug 4, 2026
Summary not yet generated.
8-K
Filed Jun 23, 2026
· Period ending Jun 23, 2026
Summary not yet generated.
10-Q
Filed Jun 17, 2026
· Period ending Mar 31, 2026
revenue $0, net income -$38.3M. Odyssey Therapeutics posts first 10-Q: cash, quarterly loss, runway into H2 2028
5 material changes detected. Sign up free to read the summary.
8-K
Filed Jun 17, 2026
· Period ending Jun 17, 2026
Summary not yet generated.
8-K
Filed May 11, 2026
· Period ending May 7, 2026
Summary not yet generated.
S-1/A
Filed May 4, 2026
Critical
Odyssey Therapeutics files for IPO, plans to offer 13.24M shares at $17.00 each, raising $225.1M gross
7 material changes detected. Sign up free to read the summary.
Latest financial statements
From 10-Q filed Aug 6, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share data)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | — | 959 | — | 2,877 |
| Operating expenses: | ||||
| Research and development | 36,226 | 30,227 | 68,547 | 69,001 |
| General and administrative | 10,511 | 13,219 | 17,861 | 21,171 |
| Change in fair value of contingent consideration | 8,733 | (566) | 8,842 | (6,214) |
| Total operating expenses | 55,470 | 42,880 | 95,250 | 83,958 |
| Operating loss | (55,470) | (41,921) | (95,250) | (81,081) |
| Other income (expense), net: | ||||
| Interest income | 2,832 | 872 | 4,540 | 2,028 |
| Interest expense | (20) | (2) | (30) | (4) |
| Other expense, net | (138) | (154) | (255) | (443) |
| Total other income, net | 2,674 | 716 | 4,255 | 1,581 |
| Loss before income taxes | (52,796) | (41,205) | (90,995) | (79,500) |
| Income tax provision | (8) | 30 | 55 | 170 |
| Net loss | (52,788) | (41,235) | (91,050) | (79,670) |
| Other comprehensive (loss) income: | ||||
| Foreign currency translation adjustment | 113 | 1,314 | (193) | 1,889 |
| Unrealized gain (loss) on marketable securities, net of tax | (471) | 5 | (557) | (5) |
| Total other comprehensive (loss) income | (358) | 1,319 | (750) | 1,884 |
| Comprehensive loss | (53,146) | (39,916) | (91,800) | (77,786) |
| Net loss attributable to common stockholders (see Note 15) | (52,788) | (41,235) | (91,050) | (79,670) |
| Net loss per share attributable to common stockholders, basic and diluted | (1.74) | (29.54) | (5.05) | (67.11) |
| Weighted-average common stock outstanding, basic and diluted | 30,277,051 | 1,395,695 | 18,034,399 | 1,187,080 |
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share data)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 82,031 | 41,687 |
| Short-term marketable securities | 228,544 | 139,671 |
| Prepaid expenses and other current assets | 10,887 | 9,298 |
| Total current assets | 321,462 | 190,656 |
| Property and equipment, net | 4,876 | 7,209 |
| Right-of-use assets | 17,040 | 18,804 |
| Goodwill | 14,100 | 14,327 |
| Intangible asset | 86 | 262 |
| Long-term marketable securities | 122,494 | 35,198 |
| Other non-current assets | 3,792 | 3,332 |
| Total assets | 483,850 | 269,788 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | 7,668 | 7,872 |
| Accrued expenses and other current liabilities | 15,162 | 13,392 |
| Lease liabilities, current | 5,465 | 5,211 |
| Total current liabilities | 28,295 | 26,475 |
| Contingent consideration and warrant liability | 14,974 | 6,133 |
| Lease liabilities, non-current | 19,360 | 21,900 |
| Total liabilities | 62,629 | 54,508 |
| Commitments and contingencies (see Note 13) | ||
| Series A convertible preferred stock, $0.0001 par value: no shares and 43,749,045 shares authorized as of June 30, 2026 and December 31, 2025, respectively; and no shares and 43,732,797 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively (liquidation preference $0 and $84,796 as of June 30, 2026 and December 31, 2025, respectively) | - | 216,503 |
| Series B convertible preferred stock, $0.0001 par value: no shares and 26,601,360 shares authorized as of June 30, 2026 and December 31, 2025, respectively; and no shares and 26,601,360 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively (liquidation preference $0 and $66,100 as of June 30, 2026 and December 31, 2025, respectively) | - | 167,765 |
| Series C convertible preferred stock, $0.0001 par value: no shares and 24,901,598 shares authorized as of June 30, 2026 and December 31, 2025, respectively; and no shares and 24,901,598 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively (liquidation preference $0 and $49,065 as of June 30, 2026 and December 31, 2025, respectively) | - | 123,259 |
| Series D convertible preferred stock, $0.0001 par value: no shares and 142,016,823 shares authorized as of June 30, 2026 and December 31, 2025, respectively; and no shares and 141,950,377 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively (liquidation preference $0 and $213,631 as of June 30, 2026 and December 31, 2025), respectively | - | 196,031 |
| Stockholders’ deficit: | ||
| Common stock, $0.0001 par value: 500,000,000 and 365,081,240 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 48,031,320 shares and 2,472,757 shares issued as of June 30, 2026 and December 31, 2025, respectively; 47,891,251 shares and 2,306,207 shares outstanding as of June 30, 2026 and December 31, 2025, respectively | 5 | - |
| Preferred stock, $0.0001 par value: 50,000,000 shares and no shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | - | - |
| Additional paid-in capital | 1,080,910 | 79,616 |
| Accumulated deficit | (659,189) | (568,139) |
| Accumulated other comprehensive income (loss) | (505) | 245 |
| Total stockholders’ equity (deficit) | 421,221 | (488,278) |
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | 483,850 | 269,788 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | (91,050) | (79,670) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,214 | 2,566 |
| Loss from disposal of property and equipment | 606 | 380 |
| Right-of-use asset impairment expense | — | 5,440 |
| Accretion of discount on marketable securities | (225) | (732) |
| Stock-based compensation expense | 8,258 | 6,687 |
| Non-cash rent expense | 1,757 | 1,523 |
| Change in fair value of contingent consideration and warrant liability | 8,913 | (6,214) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,588) | (245) |
| Other non-current assets | (217) | 5,058 |
| Accounts payable | (313) | 991 |
| Lease liabilities | (2,480) | (1,908) |
| Accrued expenses and other current liabilities | (1,418) | (6,758) |
| Net cash used in operating activities | (75,543) | (72,882) |
| Cash flows from investing activities: | ||
| Maturities of marketable securities | 69,900 | 58,250 |
| Purchases of marketable securities | (246,489) | - |
| Proceeds from sale of property and equipment | 281 | 138 |
| Purchases of property and equipment | (334) | (956) |
| Net cash (used in) provided by investing activities | (176,642) | 57,432 |
| Cash flows from financing activities: | ||
| Proceeds from the exercise of common stock options | 1,237 | 235 |
| Proceeds from the exercise of common stock warrants | — | 6 |
| Principal payments on finance leases | (70) | (70) |
| Proceeds from the issuance of common stock upon IPO, net of offering costs | 291,477 | — |
| Proceeds from the issuance of convertible preferred stock, net of issuance costs | — | 118,752 |
| Net cash provided by financing activities | 292,644 | 118,923 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 128 | 392 |
| Increase in cash, cash equivalents and restricted cash | 40,587 | 103,865 |
| Cash, cash equivalents and restricted cash, beginning of period | 44,897 | 62,346 |
| Cash, cash equivalents and restricted cash, end of period | 85,484 | 166,211 |
| Cash and cash equivalents, end of period | 82,031 | 163,001 |
| Restricted cash, included in other non-current assets, end of period | 3,453 | 3,210 |
| Total cash, cash equivalents and restricted cash, end of period | 85,484 | 166,211 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | 125 | 164 |
| Cash paid for interest | 14 | 2 |
| Supplemental disclosure of non-cash financing and investing activities: | ||
| Offering costs included in accounts payable and accrued expenses and other current liabilities | 3,303 | — |
| Right-of-use assets obtained in exchange for new finance lease liabilities | 278 | — |
| Remeasurement of right-of-use assets and lease liabilities | — | — |
| Conversion of preferred stock and preferred stock warrants into common stock and common stock warrants, upon initial public offering | 703,630 | — |
| Conversion of preferred stock into common stock | — | 7,366 |
| Unrealized loss on marketable securities | 644 | 35 |
Amounts as printed on the EDGAR/iXBRL face — (in thousands, except share and per share data); (in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗